Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06229366 |
| Title | [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL) |
| Acronym | ACCEL |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University Health Network - Princess Margaret Cancer Centre | RECRUITING | Toronto | Ontario | M5G 2M9 | Canada | Details |
| McGill University Health Centre | RECRUITING | Montréal | Quebec | H3H 2L9 | Canada | Details |